Imperative Care Reacquires Truvic, Raises $260m To Advance Neurovascular And Peripheral Interventions
The proceeds from the series D financing will help Imperative Care advance its stroke-intervention technologies and Truvic’s peripheral intervention devices.
You may also be interested in...
The Israeli company raised $16m to support its Augmented Respiration Technology, a novel approach for delivering oxygen directly into the venous system. The company expects to earn FDA clearance for first product by 2023.
Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.
Johnson & Johnson’s medical device sales were up nearly 60% year-over-year in the second quarter of 2021 while Abbott reported 51% growth in its device business, reflecting the recovery in procedure volumes since the worst days of the pandemic in mid-2020.